- Details
- Preston Sprenkle and Eric Kim discuss the future of prostate cancer diagnostics, emphasizing the role of genomic classifiers like PAM50 and MRI in refining patient treatment plans. Dr. Kim suggests that prostate cancer care may soon parallel advances in breast cancer, utilizing gene pathway analyses to guide treatment decisions more accurately. They explore how integrating complex biomarkers into...
|
- Details
- Preston Sprenkle discusses with Eric Kim the integration of MRI and genomic classifiers in prostate cancer management. They explore the potential of artificial intelligence (AI) to enhance diagnostic accuracy and personalization of treatment. Dr. Kim reflects on his project, which investigates correlations between MRI findings and genomic data from a large cohort, noting the challenges of consiste...
|
- Details
- Eric Kim discusses the variation in prostate cancer genomic subtypes related to MRI PI-RADS scores and racial differences. He focused on the correlations between mpMRI findings and the Decipher genomic classifier in a racially diverse cohort of men. The study revealed that MRI and Decipher scores generally correlated well, especially in non-African Americans, but this correlation was weaker among...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the 2024 updates to the NCCN Prostate Cancer Guidelines, highlighting the integration of the Decipher Genomic Classifier tests across various stages of prostate cancer management. This detailed conversation explores the progression from the 2023 guidelines, emphasizing the evolution of risk stratification tools from prognostic to the now predictive capabilit...
|
- Details
- Neil Desai and Paul Nguyen discuss the integration of the Decipher® genomic biomarker in prostate cancer treatment. The conversation centers on two trials, NRG-GU009 and GU010, which utilize Decipher® genomic classifiers to tailor treatment intensity, particularly in hormonal therapy. Dr. Nguyen emphasizes the shift from traditional metrics like PSA and Gleason scores to more precise genomic class...
|
- Details
- Aditya Bagrodia hosts Daniel Spratt to discuss the complexities of gene expression classifiers in prostate cancer. Dr. Spratt's team conducted a study involving over 50,000 patients to evaluate the interchangeability of three major gene classifiers: Decipher, Oncotype, and Polaris. Contrary to common belief, the study reveals that these tests are not functionally interchangeable, showing only mode...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the publication on genomic classifier performance in intermediate-risk prostate cancer, focusing on the results of the NRG Oncology/RTOG 01-26 randomized Phase 3 trial. The study explores the use of the Decipher 22-gene genomic classifier in risk stratification, outperforming other common risk classification systems for prostatectomy and pre-treatment biopsy...
|
- Details
- Ashley Ross and Jim Hu discuss the use of genomic classifiers, specifically the Decipher Genomic Classifier, in the management of localized prostate cancer. They review its performance in larger datasets and its association with prostate cancer outcomes. The conversation also delves into the use of the Decipher Prostate Biopsy Test in men with favorable risk disease undergoing conservative managem...
|
- Details
- Katie Murray and Anne Lizardi-Calvaresi discuss a clinical pathway approach for using the Decipher prostate cancer genomic classifier. Reviewing the level-one evidence described in the NCCN guidelines, they discuss best practices as clinicians integrate prostate cancer genomic classifiers into the care of their patients. They highlight how the test is integrated into the workflow for patient navig...
|
- Details
- Alicia Morgans and Ashley Ross discuss how the Decipher® prognostic biomarker prostate classifier is being integrated into phase II and III clinical trials, a 22-gene prognostic biomarker that provides a score that indicates the aggressiveness of an individual patient’s cancer, to help healthcare professionals more accurately categorize risk and select appropriate treatment. The pair highlights da...
|
